Global Fibromyalgia Market Size Exceed To USD 2.59 Billion by 2035 | CAGR of 6.89% : Market Study Report

• As per Spherical Insights  Consulting, The Global Fibromyalgia Market is Expected to grow from USD 2.59 Billion in 2024 to USD 5.39 Billion by 2035, at a CAGR of 6.89% during the forecast period 2025 to 2035, owing to the launch of new therapies in the market and the rise in the number of cases.

 

• The leading Fibromyalgia Market Companies such as Pfizer, Eli Lilly, AbbVie, Tonix Pharmaceuticals, Teva Pharmaceuticals, Sun Pharmaceutical, Allergan, Novartis, Astellas Pharma, Sanofi, Johnson & Johnson, Merck & Co., Takeda Pharmaceuticals, Boehringer Ingelheim, GlaxoSmithKline, and Others.

Fibromyalgia Treatment Market: Understanding and Treatment Algorithm:

Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties, often referred to as "fibro fog." The exact cause is unknown, but it’s believed to involve abnormal pain processing in the brain. It affects mostly women and can significantly impact daily functioning.

Fibromyalgia Diagnosis:

Fibromyalgia diagnosis is primarily clinical, based on a patient’s history of widespread pain lasting over three months, along with symptoms like fatigue and sleep disturbances. There are no definitive lab tests; diagnosis involves ruling out other conditions and using criteria from organizations like the American College of Rheumatology.

 

Fibromyalgia Treatment

Fibromyalgia treatment focuses on symptom management through a combination of medication, physical therapy, lifestyle changes, and psychological support. Common treatments include pain relievers, antidepressants, exercise, cognitive behavioural therapy (CBT), and sleep management strategies. An individualized, multidisciplinary approach is often most effective for improving quality of life and daily functioning.

 

Fibromyalgia Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of Fibromyalgia, Gender-specific Diagnosed Incidence of Fibromyalgia, Type-specific Diagnosed Incidence of Fibromyalgia, Age-specific Diagnosed Incidence of Fibromyalgia, Diagnosed Incident Population based on Primary Site of Fibromyalgia, and Diagnosed Incident Population based on Histologic Classification of Fibromyalgia Tumour in the global market covering North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa from 2024 to 2035.

 

Principal Insights

This section offers a global overview of fibromyalgia epidemiology in major markets worldwide.

Country Wise Fibromyalgia Multiforme Epidemiology 
   The epidemiology segment provides fibromyalgia prevalence data and finding across key region worldwide, including North America, Europe (Germany, France, Italy Spain, and united Kingdom), Asia pacific (including Japan), Latin America, the Middle East, and Africa.

fibromyalgia-market

 

Fibromyalgia Marketed Drugs:

• Lyrica: Pfizer

Lyrica (pregabalin) is an alpha  2  delta ligand that modulates calcium channels in the central nervous system to reduce neuronal excitability. It is FDA  approved for fibromyalgia and helps manage widespread pain, sleep disturbances, and anxiety symptoms commonly associated with the condition.

• Cymbalta: Eli Lilly

Cymbalta (duloxetine) is a serotonin  norepinephrine reuptake inhibitor (SNRI) approved by the FDA for fibromyalgia. It works by enhancing neurotransmitter levels in the brain, helping reduce pain sensitivity and improve mood and energy levels in fibromyalgia patients.

• Savella: AbbVie (formerly Forest Laboratories)

Savella (milnacipran) is an SNRI specifically approved for the management of fibromyalgia in adults. It increases serotonin and norepinephrine activity in the brain to help alleviate pain, fatigue, and cognitive dysfunction, although it is not approved for depression in the U.S.

 

Fibromyalgia: Emerging Therapies

• TNX  102 SL: It is a sublingual tablet formulation of cyclobenzaprine in Phase 3 trials for fibromyalgia. It is designed to improve sleep and reduce pain by targeting central nervous system pathways involved in chronic pain and sleep disturbance.
• Stanza: It is a digital therapeutic using Acceptance and Commitment Therapy (ACT) for fibromyalgia management. It delivers structured behavioral interventions via a mobile app and has shown significant improvements in pain, fatigue, and quality of life in clinical trials.
• SP  26: It is a ketamine  loaded implant under development for fibromyalgia. It provides sustained drug release to reduce chronic pain and limit side effects, aiming for long  term symptom relief in patients with treatment  resistant fibromyalgia.
• LDN: It is being repurposed as a fibromyalgia treatment. It modulates glial cell activity and inflammation, aiming to reduce central sensitization and chronic pain symptoms in fibromyalgia patients who do not respond well to conventional medications.

• fibromyalgia patients who do not respond well to conventional medications.

 

Fibromyalgia Market Outlook

• The fibromyalgia market encompasses diagnostics, medications, and therapeutic approaches aimed at managing chronic musculoskeletal pain, fatigue, and cognitive disturbances. It involves pharmaceutical companies, diagnostics providers, and pain management therapies catering to a rising population affected by this often misunderstood and underdiagnosed condition.
• Rising awareness of fibromyalgia, advancements in diagnostics, and increasing prevalence—especially among aging and female populations—are key drivers. Demand for effective symptom management, alongside new drug developments and better patient support initiatives, continues to push the market forward across both developed and emerging healthcare systems.
• Unmet clinical needs, growing research into neuroinflammatory pathways, and rising adoption of multidisciplinary treatments offer strong growth potential. Digital health tools, wearable diagnostics, and increased funding for pain research open doors for innovation, especially in personalized therapy and novel drug delivery systems.
• Governments worldwide are promoting fibromyalgia awareness, funding chronic pain research, and integrating fibromyalgia management into national health strategies. Institutions like the NIH and EMA support clinical trials and encourage standardized treatment frameworks, improving diagnosis rates and access to quality care.
• Lack of clear diagnostic criteria and limited curative treatment options hinder accurate diagnosis and long  term disease management.
• The fibromyalgia market is projected to grow steadily due to rising patient awareness, improved diagnostic capabilities, and expanding treatment pipelines.

 

Fibromyalgia Market Segmentation

 

By Diagnosis: 

• Blood Tests
• Others

Blood Tests hold the largest share in the diagnosis segment of the fibromyalgia market due to their role in ruling out other conditions with similar symptoms. They are commonly used as a first  line diagnostic tool, making them essential and widely adopted in clinical settings for differential diagnosis.

 

By Treatment:

• Medication
• Therapy
• Others

Medication dominates the treatment segment because it offers quick symptom relief and is often the first treatment approach for fibromyalgia. FDA  approved drugs like pregabalin and duloxetine are widely prescribed, and ongoing pharmaceutical innovations further reinforce the dominance of medication over other treatment options like therapy or lifestyle changes.

 

Regional Segment Analysis of the Fibromyalgia Market

 

North America holds the largest share in the fibromyalgia market due to high disease awareness, advanced healthcare infrastructure, and widespread access to approved medications like Lyrica and Cymbalta. The region benefits from robust diagnostic capabilities, increased research funding, and a strong presence of leading pharmaceutical companies. Additionally, supportive regulatory frameworks and rising public health initiatives contribute to early diagnosis and better disease management, further solidifying North America’s market dominance.

 

Asia  Pacific is the fastest  growing region in the fibromyalgia market, driven by increasing awareness, improving healthcare access, and a rising patient population. Rapid urbanization and growing investment in healthcare infrastructure are boosting diagnosis rates. Countries like India, China, and Japan are seeing expanding clinical research and therapeutic adoption. Government efforts to improve chronic pain management and greater interest in alternative therapies also contribute to the region’s accelerating market growth.

 

Fibromyalgia Market Key Companies

• Pfizer
• Eli Lilly
• AbbVie
• Tonix Pharmaceuticals
• Teva Pharmaceuticals
• Sun Pharmaceutical
• Allergan
• Novartis
• Astellas Pharma
• Sanofi
• Johnson & Johnson
• Merck & Co.
• Takeda Pharmaceuticals
• Boehringer Ingelheim
• GlaxoSmithKline
• Others

 

Fibromyalgia Therapeutics Market Report Scope

• The Fibromyalgia therapeutics market report provides a detailed overview, covering its causes, symptoms, disease progression, and existing treatment options.
• Detailed insights into Fibromyalgia’s epidemiology and therapeutic approaches are included.
• Additionally, a comprehensive review of existing and emerging Fibromyalgia therapies is provided, including an evaluation of new treatments expected to influence the current Fibromyalgia treatment market landscape.
• The report includes a detailed review of the Fibromyalgia therapeutics market, both historical and forecasted, highlighting the global drug reach.
• The Patient  Based Fibromyalgia Market Forecasting report offers valuable insights into trends shaping the global Fibromyalgia market, helping to develop effective business strategies.

 

Fibromyalgia Treatment Market Report Insights

• Forecasting Market Trends Based on Patient Data and Disease Rates
• Fibromyalgia Therapeutic Approaches in Fibromyalgia
• Review Of Drugs in Development for Fibromyalgia
• Market, Growth, and Trends in Fibromyalgia
• Market Opportunities in Fibromyalgia Treatment
• Effects Of Future Therapies on Fibromyalgia Treatment.

 

Fibromyalgia Treatment Market Report Key Strengths

• 15 Years Fibromyalgia Market Forecast
• Global Coverage
• Fibromyalgia Epidemiology Segmentation
• Key Cross Competition

 

Fibromyalgia Treatment Market Report Assessment

• Present Practices in the Fibromyalgia Treatment Market
• Review of Investigational Fibromyalgia Drugs
• Attractiveness of the Fibromyalgia Drug Market
• Fibromyalgia Market Drivers
• Fibromyalgia Market Barriers
• SWOT
• Attribute Analysis

 

 

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the fibromyalgia market based on the below  mentioned segments:

 

Global Fibromyalgia Market, By Diagnosis

• Blood Tests
• Others

 

Global Fibromyalgia Market, By Treatment

• Medication
• Therapy
• Others

 

Global Fibromyalgia Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain